​
​

Harrow Health (HROW) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HROW Stock Forecast

Harrow Health stock forecast is as follows: an average price target of $49.50 (represents a 15.49% upside from HROW’s last price of $42.86) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

HROW Price Target

The average price target for Harrow Health (HROW) is $49.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $73.00 to $25.00. This represents a potential 15.49% upside from HROW's last price of $42.86.

HROW Analyst Ratings

Buy

According to 5 Wall Street analysts, Harrow Health's rating consensus is 'Buy'. The analyst rating breakdown for HROW stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Harrow Health Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 18, 2024Sahil KazmiB.Riley Financial$73.00$56.4129.41%70.32%
Oct 04, 2024Brooks O'NeilLake Street$55.00$49.7510.55%28.32%
Aug 09, 2024Chase KnickerbockerCraig-Hallum$45.00$35.2527.66%4.99%
Jun 21, 2024Chase KnickerbockerCraig-Hallum$30.00$19.9350.53%-30.00%
Jun 03, 2024Brooks O'NeilLoop Capital Markets$25.00$17.6841.44%-41.67%
Jun 03, 2024Brooks O'NeilLake Street$25.00$18.1337.93%-41.67%
Row per page
Go to

The latest Harrow Health stock forecast, released on Oct 18, 2024 by Sahil Kazmi from B.Riley Financial, set a price target of $73.00, which represents a 29.41% increase from the stock price at the time of the forecast ($56.41), and a 70.32% increase from HROW last price ($42.86).

Harrow Health Price Target by Period

1M3M12M
# Anlaysts126
Avg Price Target$73.00$64.00$42.17
Last Closing Price$42.86$42.86$42.86
Upside/Downside70.32%49.32%-1.61%

In the current month, the average price target of Harrow Health stock is $73.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 70.32% increase as opposed to Harrow Health's last price of $42.86. This month's average price target is up 14.06% compared to last quarter, and up 73.11% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 04, 2024J.P. MorganBuyBuyHold
Oct 04, 2024Craig-HallumBuyBuyHold
Oct 04, 2024Lake StreetBuyBuyHold
Aug 29, 2024Lake StreetBuyBuyHold
Aug 09, 2024Craig-HallumBuyBuyHold
Aug 09, 2024B. RileyBuyBuyHold
Jun 21, 2024Craig-HallumBuyBuyHold
Jun 03, 2024Lake StreetBuyBuyHold
May 15, 2024Craig-HallumBuyBuyHold
May 15, 2024B. RileyBuyBuyHold
Row per page
Go to

Harrow Health's last stock rating was published by J.P. Morgan on Oct 04, 2024. The company gave HROW a "Buy" rating, the same as its previous rate.

Harrow Health Financial Forecast

Harrow Health Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$36.35M$34.27M$33.47M$26.10M$20.33M$22.82M$23.32M$22.12M$20.19M$18.71M$18.13M$15.44M$14.60M$14.40M$8.06M$11.82M$12.60M$12.76M
Avg Forecast$103.40M$96.80M$89.80M$79.00M$79.40M$72.65M$66.95M$58.15M$65.30M$52.80M$42.51M$36.32M$37.86M$37.58M$31.04M$25.13M$21.40M$23.14M$22.07M$19.48M$19.35M$17.44M$15.71M$14.01M$14.45M$9.34M$5.70M$11.77M$13.66M$12.85M
High Forecast$111.75M$104.62M$97.05M$85.38M$85.81M$78.52M$72.36M$58.22M$70.57M$53.13M$45.94M$36.79M$40.91M$37.64M$33.55M$27.16M$23.13M$23.14M$22.07M$19.48M$19.35M$17.44M$15.71M$14.01M$14.45M$9.34M$5.70M$11.77M$13.66M$12.85M
Low Forecast$98.94M$92.62M$85.92M$75.59M$75.97M$69.51M$64.06M$58.08M$62.48M$52.48M$40.67M$35.84M$36.22M$37.53M$29.70M$24.05M$20.48M$23.14M$22.07M$19.48M$19.35M$17.44M$15.71M$14.01M$14.45M$9.34M$5.70M$11.77M$13.66M$12.85M
# Analysts111111122111211111111111117986
Surprise %------------0.96%0.91%1.08%1.04%0.95%0.99%1.06%1.14%1.04%1.07%1.15%1.10%1.01%1.54%1.41%1.00%0.92%0.99%

Harrow Health's average Quarter revenue forecast for Mar 24 based on 1 analysts is $36.32M, with a low forecast of $35.84M, and a high forecast of $36.79M. HROW's average Quarter revenue forecast represents a -0.10% decrease compared to the company's last Quarter revenue of $36.35M (Dec 23).

Harrow Health EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111122111211111111111117986
EBITDA------------$-1.61M$1.74M$2.35M$1.21M$-1.78M$-2.78M$5.00K$162.00K$11.25M$-3.86M$3.78M$-585.00K$3.63M$1.26M$-3.44M$-851.00K$-1.43M$9.79M
Avg Forecast$-38.55K$-36.09K$-33.48K$-29.45K$-29.60K$-27.08K$-24.96K$-21.68K$-24.34K$-19.68K$-15.85K$-13.54K$-14.11K$-14.01K$-11.57K$-9.37K$-7.98K$995.13K$949.16K$277.69K$831.96K$749.73K$675.42K$1.76M$621.19K$401.51K$245.11K$-12.85M$587.50K$552.69K
High Forecast$-36.88K$-34.53K$-32.03K$-28.18K$-28.32K$-25.91K$-23.88K$-21.65K$-23.29K$-19.56K$-15.16K$-13.36K$-13.50K$-13.99K$-11.07K$-8.96K$-7.63K$995.13K$949.16K$333.23K$831.96K$749.73K$675.42K$2.11M$621.19K$401.51K$245.11K$-10.28M$587.50K$552.69K
Low Forecast$-41.66K$-39.00K$-36.18K$-31.83K$-31.99K$-29.27K$-26.97K$-21.70K$-26.31K$-19.80K$-17.13K$-13.72K$-15.25K$-14.03K$-12.51K$-10.13K$-8.62K$995.13K$949.16K$222.15K$831.96K$749.73K$675.42K$1.41M$621.19K$401.51K$245.11K$-15.42M$587.50K$552.69K
Surprise %------------114.23%-124.48%-203.25%-129.16%222.86%-2.79%0.01%0.58%13.53%-5.15%5.59%-0.33%5.84%3.13%-14.02%0.07%-2.43%17.71%

2 analysts predict HROW's average Quarter EBITDA for Dec 23 to be $-14.11K, with a high of $-13.50K and a low of $-15.25K. This is -100.81% lower than Harrow Health's previous annual EBITDA (Sep 23) of $1.74M.

Harrow Health Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111122111211111111111117986
Net Income------------$-9.15M$-4.39M$-4.23M$-6.64M$1.05M$-6.46M$-6.24M$-2.30M$-7.42M$-8.33M$-6.82M$217.00K$1.15M$8.64M$-237.00K$-12.91M$7.41M$-11.47M
Avg Forecast$18.52M$14.96M$10.33M$7.48M$8.37M$6.59M$3.38M$1.07M$5.97M$-1.87M$-6.53M$-7.75M$-1.54M$1.31M$-1.42M$-1.90M$-4.16M$-178.09K$-712.38K$-2.25M$-1.51M$-623.33K$1.19M$439.43K$178.09K$-3.38M$-6.06M$-14.20M$178.09K$-1.25M
High Forecast$20.47M$16.53M$11.41M$8.27M$9.25M$7.28M$3.74M$1.18M$6.59M$-1.77M$-6.16M$-7.31M$-1.46M$1.44M$-1.34M$-1.79M$-3.92M$-178.09K$-712.38K$-1.80M$-1.51M$-623.33K$1.19M$527.31K$178.09K$-3.38M$-6.06M$-11.36M$178.09K$-1.25M
Low Forecast$17.48M$14.12M$9.75M$7.06M$7.90M$6.22M$3.19M$1.01M$5.63M$-2.07M$-7.22M$-8.56M$-1.71M$1.23M$-1.57M$-2.10M$-4.59M$-178.09K$-712.38K$-2.70M$-1.51M$-623.33K$1.19M$351.54K$178.09K$-3.38M$-6.06M$-17.04M$178.09K$-1.25M
Surprise %------------5.93%-3.36%2.97%3.50%-0.25%36.30%8.76%1.02%4.90%13.36%-5.74%0.49%6.45%-2.55%0.04%0.91%41.61%9.20%

Harrow Health's average Quarter net income forecast for Mar 23 is $-1.90M, with a range of $-2.10M to $-1.79M. HROW's average Quarter net income forecast represents a -280.06% decrease compared to the company's last Quarter net income of $1.05M (Dec 22).

Harrow Health SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111122111211111111111117986
SG&A------------$26.21M$21.03M$19.96M$15.89M$15.24M$15.42M$14.19M$13.40M$12.67M$11.36M$9.12M$8.16M$7.44M$8.44M$6.95M$8.42M$7.70M$8.61M
Avg Forecast$65.18M$61.02M$56.61M$49.80M$50.05M$45.80M$42.20M$36.66M$41.16M$33.29M$26.80M$22.89M$23.86M$23.69M$19.57M$15.84M$13.49M$14.59M$13.92M$12.36M$12.20M$10.99M$9.90M$8.83M$9.11M$5.89M$3.59M$9.26M$8.61M$8.10M
High Forecast$70.44M$65.95M$61.18M$53.82M$54.09M$49.50M$45.61M$36.70M$44.49M$33.49M$28.96M$23.19M$25.79M$23.73M$21.15M$17.12M$14.58M$14.59M$13.92M$14.83M$12.20M$10.99M$9.90M$8.83M$9.11M$5.89M$3.59M$11.11M$8.61M$8.10M
Low Forecast$62.37M$58.39M$54.16M$47.65M$47.89M$43.82M$40.38M$36.62M$39.39M$33.08M$25.64M$22.59M$22.83M$23.66M$18.72M$15.16M$12.91M$14.59M$13.92M$9.89M$12.20M$10.99M$9.90M$8.83M$9.11M$5.89M$3.59M$7.41M$8.61M$8.10M
Surprise %------------1.10%0.89%1.02%1.00%1.13%1.06%1.02%1.08%1.04%1.03%0.92%0.92%0.82%1.43%1.94%0.91%0.89%1.06%

Harrow Health's average Quarter SG&A projection for Mar 24 is $22.89M, based on 1 Wall Street analysts, with a range of $22.59M to $23.19M. The forecast indicates a -12.66% fall compared to HROW last annual SG&A of $26.21M (Dec 23).

Harrow Health EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111122111211111111111117986
EPS------------$-0.26$-0.13$-0.14$-0.22$0.04$-0.24$-0.23$-0.08$-0.27$-0.39$-0.26$0.08$0.04$0.66$0.16$-0.92$0.29$-1.26
Avg Forecast$0.52$0.42$0.29$0.21$0.23$0.18$0.10$0.03$0.17$-0.05$-0.18$-0.22$-0.04$0.04$-0.04$-0.05$-0.12$-0.01$-0.02$-0.04$-0.04$-0.02$0.03$0.01$0.01$-0.10$-0.17$-0.02$0.01$-0.04
High Forecast$0.57$0.46$0.32$0.23$0.26$0.20$0.10$0.03$0.19$-0.05$-0.17$-0.21$-0.04$0.04$-0.04$-0.05$-0.11$-0.01$-0.02$-0.04$-0.04$-0.02$0.03$0.01$0.01$-0.10$-0.17$-0.02$0.01$-0.04
Low Forecast$0.49$0.40$0.27$0.20$0.22$0.17$0.09$0.03$0.16$-0.06$-0.20$-0.24$-0.05$0.03$-0.04$-0.06$-0.13$-0.01$-0.02$-0.04$-0.04$-0.02$0.03$0.01$0.01$-0.10$-0.17$-0.02$0.01$-0.04
Surprise %------------6.00%-3.55%3.50%4.13%-0.34%48.00%11.50%2.41%6.35%22.29%-7.80%5.59%8.00%-6.95%-0.94%46.00%58.00%36.00%

According to 1 Wall Street analysts, Harrow Health's projected average Quarter EPS for Mar 23 is $-0.05, with a low estimate of $-0.06 and a high estimate of $-0.05. This represents a -233.33% decrease compared to HROW previous annual EPS of $0.04 (Dec 22).

Harrow Health Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
APYXApyx Medical$1.29$8.50558.91%Buy
FENCFennec Pharmaceuticals$4.40$15.75257.95%Buy
ETONEton Pharmaceuticals$10.46$13.0024.28%Buy
HROWHarrow Health$42.86$49.5015.49%Buy

HROW Forecast FAQ

Is Harrow Health a good buy?

Yes, according to 5 Wall Street analysts, Harrow Health (HROW) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of HROW's total ratings.

What is HROW's price target?

Harrow Health (HROW) average price target is $49.5 with a range of $25 to $73, implying a 15.49% from its last price of $42.86. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Harrow Health stock go up soon?

According to Wall Street analysts' prediction for HROW stock, the company can go up by 15.49% (from the last price of $42.86 to the average price target of $49.5), up by 70.32% based on the highest stock price target, and down by -41.67% based on the lowest stock price target.

Can Harrow Health stock reach $60?

HROW's highest twelve months analyst stock price target of $73 supports the claim that Harrow Health can reach $60 in the near future.

What is Harrow Health's current price target trend?

1 Wall Street analyst forecast a $73 price target for Harrow Health (HROW) this month, up 70.32% from its last price of $42.86. Compared to the last 3 and 12 months, the average price target increased by 49.32% and decreased by -1.61%, respectively.

What are Harrow Health's analysts' financial forecasts?

Harrow Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $277.15M (high $294.9M, low $267.63M), average EBITDA is $-103K (high $-99.769K, low $-110K), average net income is $19.41M (high $21.45M, low $18.32M), average SG&A $174.71M (high $185.9M, low $168.71M), and average EPS is $0.545 (high $0.602, low $0.514). HROW's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $369M (high $398.8M, low $353.07M), average EBITDA is $-138K (high $-132K, low $-149K), average net income is $51.29M (high $56.68M, low $48.41M), average SG&A $232.61M (high $251.39M, low $222.57M), and average EPS is $1.44 (high $1.59, low $1.36).

Did the HROW's actual financial results beat the analysts' financial forecasts?

Based on Harrow Health's last annual report (Dec 2023), the company's revenue was $130.19M, which missed the average analysts forecast of $131.61M by -1.08%. Apple's EBITDA was $12.92M, missing the average prediction of $-49.062K by -26434.03%. The company's net income was $-24.411M, beating the average estimation of $-3.562M by 585.34%. Apple's SG&A was $83.09M, beating the average forecast of $82.97M by 0.15%. Lastly, the company's EPS was $-0.75, beating the average prediction of $-0.1 by 650.01%. In terms of the last quarterly report (Dec 2023), Harrow Health's revenue was $36.36M, missing the average analysts' forecast of $37.86M by -3.97%. The company's EBITDA was $-1.612M, beating the average prediction of $-14.112K by 11322.90%. Harrow Health's net income was $-9.148M, beating the average estimation of $-1.543M by 492.69%. The company's SG&A was $26.21M, beating the average forecast of $23.86M by 9.84%. Lastly, the company's EPS was $-0.26, beating the average prediction of $-0.0433 by 500.00%